{
    "nct_id": "NCT02185053",
    "title": "A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia",
    "status": "COMPLETED",
    "last_update_time": "2020-05-11",
    "description_brief": "This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Solifenacin Dose Escalation",
                    "description": "Solifenacin upward dose titration from 10 mg/day to 15 mg/day (together with donepezil 10 mg/day)"
                },
                {
                    "id": "FG001",
                    "title": "Donepezil Dose Escalation",
                    "description": "Donepezil upward dose titration up to the first intolerable dose (FID) or up to 40 mg/kg together with solifenacin 15 mg/day. End of dose escalation phase."
                },
                {
                    "id": "FG002",
                    "title": "Donepezil Dose Maintenance",
                    "description": "Donepezil upward dose titration up to the first intolerable dose (FID) or up to 40 mg/kg together with solifenacin 15 mg/day. End of Dose Maintenance phase."
                }
            ],
            "periods": [
                {
                    "title": "Solifenacin Dose Escalation Phase",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "41"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "38"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Cardiac symptoms",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "No longer meeting eligibility criteria",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Donepezil Dose Escalation Phase",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "38"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "33"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "5"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Cardiac symptoms",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "No longer meeting eligibility criteria",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Donepezil Dose Maintenance Phase",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "33"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "30"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "3"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Cardiac symptoms",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Safety Population",
                    "description": "All subjects who received at least one dose of any study drug."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "41"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "Years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "73.1",
                                            "spread": "8.2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "22"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "19"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Donepezil Maximum Tolerated Dose (MTD)",
                    "description": "Number of participants who reached Donepezil Maximum Tolerated Dose of 40 mg/day (highest allowed per protocol) at the end of donepezil dose titration phase and at the end of the maintenance phase.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Donepezil Dose Escalation",
                            "description": "Donepezil upward dose titration up to the first intolerable dose (FID) or up to 40 mg/kg together with solifenacin 15 mg/day. End of dose escalation phase."
                        },
                        {
                            "id": "OG001",
                            "title": "Donepezil Dose Maintenance",
                            "description": "Donepezil upward dose titration up to the first intolerable dose (FID) or up to 40 mg/kg together with solifenacin 15 mg/day. End of Dose Maintenance phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "33"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "33"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "15 mg/day",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "20 mg/day",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "25 mg/day",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "30 mg/day",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "35 mg/day",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "40 mg/day",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "29"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "28"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Subjects With Any TEAEs",
                    "description": "Number of subjects who experienced any treatment-emergent adverse events (TEAEs) at any time during the study.",
                    "populationDescription": "All subjects those who received at least one dose of any study drug.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Safety Population",
                            "description": "All subjects who received at least one dose of any study drug."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "41"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Serious Adverse Events (SAEs)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Non-serious AEs",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "34"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Deaths",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Donepezil Plasma Concentration at Maximum Tolerated (MTD) or Maximum Allowable Dose",
                    "description": "Donepezil Plasma Concentration pre-dose and 4 hour post-dose at Maximum Tolerated (MTD) or Maximum Allowable Dose, measured at baseline, at end of donepezil dose titration and at the end of maintenance.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/mL",
                    "timeFrame": "Day 1 (baseline) to end of study",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Solifenain Dose Escalation",
                            "description": "Solifenacin upward dose titration from 10 mg/day to 15 mg/day (together with donepezil 10 mg/day)"
                        },
                        {
                            "id": "OG001",
                            "title": "Donepezil Dose Escalation",
                            "description": "Donepezil upward dose titration up to the first intolerable dose (FID) or up to 40 mg/kg together with solifenacin 15 mg/day. End of dose escalation phase."
                        },
                        {
                            "id": "OG002",
                            "title": "Donepezil Dose Maintenance",
                            "description": "Donepezil upward dose titration up to the first intolerable dose (FID) or up to 40 mg/kg together with solifenacin 15 mg/day. End of Dose Maintenance phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "41"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "32"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Donepezil Concentration pre-dose (ng/mL)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "42.7",
                                            "spread": "20.27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "184.2",
                                            "spread": "65.95"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "188.1",
                                            "spread": "64.21"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Donepezil Concentration 4 hour post-dose (ng/mL)",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "57.2",
                                            "spread": "21.58"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "257.5",
                                            "spread": "80.56"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "269.2",
                                            "spread": "80.94"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Safety Population",
                    "description": "All subjects who received at least one dose of any study drug.",
                    "seriousNumAffected": 8,
                    "seriousNumAtRisk": 41,
                    "otherNumAffected": 33,
                    "otherNumAtRisk": 41
                }
            ],
            "seriousEvents": [
                {
                    "term": "Muscular weakness",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Pelvic fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Urosepsis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Gastric volvulus",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Syncope",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Agitation",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Acute myocardial infarction",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 41
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 7,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Abdominal discomfort",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Decreased appetite",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 41
                        }
                    ]
                },
                {
                    "term": "Tremor",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA, Version 18.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 41
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."
            },
            "pointOfContact": {
                "title": "Therapeutic Area Head",
                "organization": "Allergan, Inc",
                "email": "clinicaltrials@allergan.com",
                "phone": "714-246-4500"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "CPC-201 (combination of donepezil and solifenacin)",
        "donepezil",
        "solifenacin"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial drug CPC-201 is a co-formulation of donepezil (an acetylcholinesterase inhibitor) and solifenacin (a peripherally-acting anticholinergic). This combination is intended to allow higher tolerable doses of donepezil by reducing peripheral adverse effects, thereby increasing symptomatic cholinergic exposure to improve cognition rather than to modify underlying AD pathology. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Act: The trial title/registration lists CPC-201 and describes a Phase II, single-blind, placebo-controlled, multiple ascending dose study in Alzheimer\u2019s disease patients \u2014 confirming the intervention and study phase. \ue200cite\ue202turn0search1\ue201",
        "Act (supporting evidence): Publications and press report CPC-201 as donepezil + solifenacin, report increased maximum tolerated donepezil dose (to ~40 mg/day) with signals of enhanced cognitive/global outcomes, and describe the intent as symptomatic enhancement via higher cholinesterase inhibitor dosing. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Reflect: Donepezil and solifenacin are small-molecule drugs and the mechanism is symptomatic (cholinergic enhancement), not a biologic targeting amyloid or tau or other disease-modifying pathway. According to the provided definitions, this aligns best with the 'Cognitive enhancer' category. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Notes / Ambiguity: CPC-201 is a combination therapy (two small molecules) designed to potentiate a symptomatic cholinergic therapy; if one instead strictly categorized by chemistry (small-molecule combination) one might label it 'disease-targeted small molecule' only if the target were disease-modifying \u2014 but here the intent and published data indicate symptomatic cognitive enhancement, so 'Cognitive enhancer' is the correct classification. \ue200cite\ue202turn0search5\ue202turn0search4\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: CPC-201 is a co\u2011formulation of donepezil (an acetylcholinesterase inhibitor that increases central cholinergic neurotransmission) and solifenacin (a peripherally-acting antimuscarinic used to limit peripheral AEs). The intervention therefore modulates cholinergic neurotransmitter signaling to produce symptomatic cognitive enhancement rather than targeting amyloid, tau, inflammation, or other disease\u2011modifying pathways. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: The trial description and publications identify CPC-201 as donepezil + solifenacin and describe a Phase II single\u2011blind, multiple ascending dose study that raised the maximum tolerated donepezil dose to ~40 mg/day when co\u2011administered with solifenacin, with the stated intent of increasing symptomatic cholinergic exposure to improve cognition. These reports confirm the pharmacologic mechanism (cholinergic enhancement) and the symptomatic (not disease\u2011modifying) goal. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Mapping to CADRO, modulation of neurotransmitter systems (here, the cholinergic system via cholinesterase inhibition and antimuscarinic peripheral blockade) best fits category D) Neurotransmitter Receptors. The trial is a small\u2011molecule, symptomatic cognitive enhancer; it is not primarily targeting amyloid, tau, inflammation, synaptic protection as a disease\u2011modifying mechanism, nor is it a non\u2011therapeutic diagnostic \u2014 thus D is the most specific CADRO match. \ue200cite\ue202turn0search1\ue201",
        "Web search results (supporting evidence):",
        "- PubMed abstract and trial report: Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer\u2019s Disease \u2014 describes CPC-201 composition, Phase II study design, increased MTD to ~40 mg/day and cognitive/global outcome signals. \ue200cite\ue202turn0search0\ue201",
        "- Neurotherapeutics / Springer article (full text): Detailed description of CPC-201 rationale, pharmacology (donepezil = cholinesterase inhibitor; solifenacin = peripheral M3 antimuscarinic with limited BBB penetration), study outcomes and intent as symptomatic cholinergic enhancement. \ue200cite\ue202turn0search1\ue202turn0search3\ue201"
    ]
}